| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.95B | 6.97B | 5.83B | 6.64B | 5.70B | 3.17B |
| Gross Profit | 2.79B | 2.93B | 745.50M | 2.42B | 474.23M | 379.78M |
| EBITDA | 874.24M | 855.88M | 498.29M | 421.75M | 297.62M | 176.33M |
| Net Income | 193.73M | 192.53M | 130.03M | 129.50M | 77.06M | 27.55M |
Balance Sheet | ||||||
| Total Assets | 6.49B | 6.18B | 5.84B | 3.93B | 3.09B | 2.15B |
| Cash, Cash Equivalents and Short-Term Investments | 15.75M | 19.49M | 207.19M | 240.44M | 26.47M | 48.71M |
| Total Debt | 3.70B | 3.29B | 3.00B | 1.45B | 1.42B | 938.09M |
| Total Liabilities | 4.91B | 4.70B | 4.55B | 2.77B | 2.40B | 1.53B |
| Stockholders Equity | 1.58B | 1.48B | 1.29B | 1.16B | 678.41M | 614.24M |
Cash Flow | ||||||
| Free Cash Flow | -268.58M | -168.86M | -1.41B | -36.16M | -167.16M | -23.10M |
| Operating Cash Flow | -171.75M | 41.55M | 128.13M | 116.91M | 138.37M | -10.73M |
| Investing Cash Flow | -92.16M | -32.05M | -1.63B | -229.39M | -287.94M | -12.49M |
| Financing Cash Flow | 264.85M | -17.79M | 1.38B | 250.18M | 390.23M | 24.18M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹1.03B | 13.04 | ― | 0.42% | 13.13% | -2.13% | |
69 Neutral | ₹4.06B | 19.63 | ― | ― | 8.41% | 8.81% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | ₹1.00B | -1.31 | ― | ― | -30.97% | 80.99% | |
47 Neutral | ₹1.73B | 8.66 | ― | ― | -0.90% | -304.07% | |
38 Underperform | ₹250.92M | 6.72 | ― | ― | -3.26% | ― |
The board approved unaudited results for the quarter and nine months ended December 31, 2025, alongside the statutory limited review, confirming revenue of ₹17,690 lakh for the quarter and ₹50,735 lakh for the nine-month period, while net profit stood at ₹463 lakh and ₹1,464 lakh respectively. Management also reopened the trading window effective February 7, 2026, signaling compliance with insider-trading norms and providing clarity for investors following the review cycle.